Read the study before the headline
The examples below were chosen to illustrate different research questions. They do not estimate an overall treatment effect or rank retail products. A download contains the same records for readers who want to make their own notes.
Download the study ledger (CSV)
| Study | Ingredient, route and participants | Design and duration | Finding within scope | Limits and interests | Source |
|---|---|---|---|---|---|
| Martens2018 | NR · Oral Healthy adults aged 55–79; 30 randomised, 24 completed | Double-blind placebo-controlled crossover Two six-week periods | NAD-related metabolism changed; exploratory findings require larger trials | Selected population, short follow-up, no formal washout; not evidence for other molecules/routes or longevity Funding: NIH grants; ChromaDex supplied pills, standards and partial funding; authors declared no competing interests | Original paper |
| Yoshino2021 | NMN · Oral 25 overweight/obese postmenopausal women with prediabetes completed | Randomised placebo-controlled trial Ten weeks | Muscle insulin sensitivity improved; several other outcomes did not | Small selected population; no general-population, other-route or Elixir product conclusion Funding: Consult the original paper for full funding and conflicts; not independently extracted for this row | Original paper |
| Grant2019 | NAD+ · Intravenous infusion 11 healthy men; 8 NAD+, 3 saline | Small metabolism pilot with saline comparison Six-hour infusion; eight-hour metabolite observation | Describes short-term metabolite changes, not sustained clinical efficacy | Very small sample, short observation; not longevity or all-route safety evidence Funding: Commercial author/provider interests disclosed; consult the original declarations | Original paper |
Why these rows cannot be combined into a promise
The studies tested different interventions, populations and endpoints. A human biomarker result is different from a sustained clinical outcome. The IV pilot does not establish effects for another injection route; NR and NMN are not direct NAD+. None of these examples establishes an outcome for a finished Elixir product.
How this selection is maintained
Each row records the original source, ingredient, route, population, duration, endpoint and limitations. Sources were checked on 15 October 2026. Missing extraction details are stated rather than invented. This resource does not claim a clinician has reviewed it or that it contains every relevant study. A new paper should be appraised against the same fields before adding a row.
Use the detail responsibly
Consult the original methods, results and declarations. This selection omits study doses to avoid confusing a research intervention with consumer instructions. It is not personal advice or a recommendation to use a product.

